We believe that it could be of clinical utility to incorporate AFP levels at a precise cut-off in a staging system including also aetiology at the time of HCC diagnosis and that such system could be relevant for the management of patients with HIV-associated HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.